secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tarsus Pharmaceuticals, Inc. (TARS)
CIK:        0001819790
Form:       8-K
Filed at:   2023-04-24T23:59:59+00:00
Accession:  0001193125-23-112926
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Tarsus Pharma appoints Jeff Farrow as CFO and Chief Strategy Officer; Leo Greenstein departs
--------------------------------------------------------------------------------

- Leo Greenstein left as CFO effective April 24, 2023; employment continues through June 15, 2023.
- Jeff Farrow appointed CFO and Chief Strategy Officer effective April 24, 2023; previously CFO at Global Blood Therapeutics, ZS Pharma, and Hyperion Therapeutics.
- Farrow receives $500,000 base salary, $100,000 signing bonus (paid in two tranches), and 40% annual bonus target.
- Equity awards: RSUs and options each with $1.5M target value; RSUs vest 25% annually over 4 years starting June 15, 2024.
- Severance: 9 months base salary (non-CIC) or 12 months base plus accelerated vesting and prorated bonus (CIC).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819790/000119312523112926/0001193125-23-112926-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819790/000119312523112926/d470193d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-112926

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer